about
Importance of Drug Pharmacokinetics at the Site of ActionKinetics of drug action in disease states: towards physiology-based pharmacodynamic (PBPD) models.Pharmacokinetic Properties of Anticancer Agents for the Treatment of Central Nervous System Tumors: Update of the Literature.Atomoxetine: A Review of Its Pharmacokinetics and Pharmacogenomics Relative to Drug Disposition.Physiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approachUse of translational pharmacodynamic biomarkers in early-phase clinical studies for schizophrenia.Pharmacokinetics and pharmacodynamics of antiretrovirals in the central nervous system.Translational aspects of blood-brain barrier transport and central nervous system effects of drugs: from discovery to patients.Treating HIV Infection in the Central Nervous System.Temporal analysis of blood-brain barrier disruption and cerebrospinal fluid matrix metalloproteinases in rhesus monkeys subjected to transient ischemic stroke.An ultra high performance liquid chromatography with tandem mass spectrometry method for plasma and cerebrospinal fluid pharmacokinetics of rhein in patients with traumatic brain injury after administration of rhubarb decoction.Metronidazole and hydroxymetronidazole central nervous system distribution: 2. cerebrospinal fluid concentration measurements in patients with external ventricular drain.The impact of P-gp functionality on non-steady state relationships between CSF and brain extracellular fluid.Comparing translational population-PBPK modelling of brain microdialysis with bottom-up prediction of brain-to-plasma distribution in rat and human.Transependymal Cerebrospinal Fluid Flow: Opportunity for Drug Delivery?Novel CNS drug discovery and development approach: model-based integration to predict neuro-pharmacokinetics and pharmacodynamics.A double-blind, placebo-controlled, single ascending-dose study of remyelinating antibody rHIgM22 in people with multiple sclerosis.Clinical Pharmacokinetics and Pharmacodynamics of Drugs in the Central Nervous System.Monoclonal antibody exposure in rat and cynomolgus monkey cerebrospinal fluid following systemic administration.Clinical Trials for Disease-Modifying Therapies in Alzheimer's Disease: A Primer, Lessons Learned, and a Blueprint for the Future.
P2860
Q33648045-F1C1BD3C-A79A-478A-876A-B44A51AC6E31Q36090728-4D372A14-75C5-4EA2-BCFB-5E321F7DE5E9Q36600202-18129817-0989-4710-93D6-C0C89677DBD8Q36925745-C832E771-8B55-49E3-B77F-6299AA18C6D9Q37207750-5967C45F-3D85-4A86-A3C5-06D60546D4D4Q38170140-4A29FE86-F7B5-4C99-826E-514992628AF8Q38247035-C6B97010-C755-4480-8E5E-C94F0D65847BQ38351399-463D4901-5D6B-4911-9F95-17D9FE54E9BAQ39077816-DDD04195-567C-4E82-AE59-B2DBF869190DQ39155405-0653B37E-92DB-456A-A439-0022769E58B1Q41566211-1087863E-67B5-4211-9D6E-C11B4CF36A17Q41907570-59F04230-A968-4DF4-97AA-342AC6D7BA50Q43069428-EFF99CE1-6747-42C2-BC80-FFA71D8A51A9Q44635237-6BA0E8E1-2C30-45E6-85D4-4795EE2ED0B1Q47736742-45F7F370-E54C-4119-8BDB-DAAC8421BA70Q47949927-B2682539-C5B0-4959-833A-DB7A6B81DE8CQ49169217-C16DC5D3-70F1-409C-8CF6-E808E2AF2DABQ49721453-3E6CFBD0-FEC4-4E70-8DD4-42342A7FEEADQ52646460-D77B4788-3EEE-48EB-BB51-2CA00313602BQ55364364-09D731B4-4192-4689-B01C-414F19651DC5
P2860
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Utility of CSF in translational neuroscience.
@en
type
label
Utility of CSF in translational neuroscience.
@en
prefLabel
Utility of CSF in translational neuroscience.
@en
P2860
P1476
Utility of CSF in translational neuroscience
@en
P2093
Elizabeth C M de Lange
P2860
P2888
P304
P356
10.1007/S10928-013-9301-9
P577
2013-02-12T00:00:00Z
P5875
P6179
1040335399